I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2026 Q2, the actual value is USD 0.
EPS: As of FY2026 Q2, the actual value is USD -0.02.
EBIT: As of FY2026 Q2, the actual value is USD -1.155 M.
Cash and Liquidity
AEON Biopharma, Inc. reported cash and cash equivalents of $3,431 thousand as of June 30, 2026, an increase from $3,006 thousand as of December 31, 2025. In July 2026, the company completed an underwritten public offering, generating approximately $13.6 million in net upfront proceeds, with milestone warrants offering the potential for an additional $34.0 million in gross proceeds upon full cash exercise. Including these July 2026 proceeds, cash and cash equivalents are expected to fund operations into the first quarter of 2027. As of June 30, 2026, AEON Biopharma, Inc. reported approximately $15.3 million in cash, representing gross proceeds from the July 2026 offering. In November 2025, the company secured $6 million in near-term funding through a PIPE financing, with warrants offering an additional $7 million-plus capital opportunity. Also in November 2025, a $15 million convertible note and a $1.5 million note from Daewoong Pharmaceutical Co., LTD. were converted to equity, providing warrants with an additional $8 million-plus capital opportunity.
Operating Costs and Expenses
For the three months ended June 30, 2026, selling, general and administrative expenses were $2,991 thousand, down from $3,258 thousand in the same period of 2025. Research and development expenses significantly increased to $2,938 thousand in 2026, compared to $1,064 thousand in 2025. Total operating costs and expenses for this period rose to $5,919 thousand in 2026, from $4,338 thousand in 2025.For the six months ended June 30, 2026, selling, general and administrative expenses were $6,893 thousand, up from $6,383 thousand in 2025. Research and development expenses significantly increased to $4,973 thousand in 2026, compared to $1,889 thousand in 2025. Total operating costs and expenses for the six-month period increased to $11,851 thousand in 2026, from $4,800 thousand in 2025.
Net Loss
The net loss for the three months ended June 30, 2026, was -$1,155 thousand, an improvement from a net loss of -$6,642 thousand in the same period of 2025. For the six months ended June 30, 2026, the net loss was -$12,948 thousand, compared to a net income of $2,453 thousand in 2025.
Balance Sheet Highlights
Total liabilities decreased to $21,271 thousand as of June 30, 2026, from $60,587 thousand as of December 31, 2025. Stockholders’ deficit improved to -$15,361 thousand as of June 30, 2026, from -$55,027 thousand as of December 31, 2025.
Unique Metrics and Market Overview
AEON Biopharma, Inc. is developing ABP-450 in a neurotoxin market valued at $3.5 billion in 2026, projected to grow to $5.1 billion by 2031, representing a 7.7% Compound Annual Growth Rate (CAGR) in the U.S. therapeutic botulinum market. This market has grown by over 75% since 2020, with BOTOX® holding approximately 92% of the therapeutic neurotoxin market value in 2025. Neurology accounts for over 70% of the total therapeutic toxin market. Jeuveau®, the toxin powering ABP-450, generated $272.3 million in sales in 2025 for cosmetic indications.
Outlook and Guidance
AEON Biopharma, Inc. anticipates receiving additional FDA feedback in the second half of 2026, which is expected to inform the next phase of the ABP-450 biosimilar development program, including clinical pharmacology and comparative clinical study requirements. The company projects that its upfront financing proceeds will provide a cash runway into the first quarter of 2027, supporting continued advancement of the ABP-450 program and ongoing analytical and regulatory activities. The company expects to complete the majority of its remaining analytical work in 2026 and aims for ABP-450 to be priced below BOTOX®, advancing towards full-label biosimilarity.